vs

Side-by-side financial comparison of NOV Inc. (NOV) and BeOne Medicines Ltd. (ONC). Click either name above to swap in a different company.

NOV Inc. is the larger business by last-quarter revenue ($2.1B vs $1.5B, roughly 1.4× BeOne Medicines Ltd.). BeOne Medicines Ltd. runs the higher net margin — 4.4% vs 1.0%, a 3.5% gap on every dollar of revenue. On growth, BeOne Medicines Ltd. posted the faster year-over-year revenue change (32.8% vs -9.9%). BeOne Medicines Ltd. produced more free cash flow last quarter ($379.8M vs $51.0M). Over the past eight quarters, BeOne Medicines Ltd.'s revenue compounded faster (41.2% CAGR vs -3.8%).

NOV Inc., formerly National Oilwell Varco, is an American multinational corporation based in Houston, Texas. It is a worldwide provider of equipment and components used in oil and gas drilling and production operations, oilfield services, and supply chain integration services to the upstream oil and gas industry. The company conducts operations in more than 500 locations across six continents, operating through two reporting segments: Energy Equipment and Energy Products and Services.

BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.

NOV vs ONC — Head-to-Head

Bigger by revenue
NOV
NOV
1.4× larger
NOV
$2.1B
$1.5B
ONC
Growing faster (revenue YoY)
ONC
ONC
+42.7% gap
ONC
32.8%
-9.9%
NOV
Higher net margin
ONC
ONC
3.5% more per $
ONC
4.4%
1.0%
NOV
More free cash flow
ONC
ONC
$328.8M more FCF
ONC
$379.8M
$51.0M
NOV
Faster 2-yr revenue CAGR
ONC
ONC
Annualised
ONC
41.2%
-3.8%
NOV

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
NOV
NOV
ONC
ONC
Revenue
$2.1B
$1.5B
Net Profit
$20.0M
$66.5M
Gross Margin
18.5%
90.5%
Operating Margin
2.3%
12.4%
Net Margin
1.0%
4.4%
Revenue YoY
-9.9%
32.8%
Net Profit YoY
-73.0%
143.8%
EPS (diluted)
$0.05
$0.05

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
NOV
NOV
ONC
ONC
Q1 26
$2.1B
Q4 25
$2.3B
$1.5B
Q3 25
$2.2B
$1.4B
Q2 25
$2.2B
$1.3B
Q1 25
$2.1B
$1.1B
Q4 24
$2.3B
$1.1B
Q3 24
$2.2B
$1.0B
Q2 24
$2.2B
$929.2M
Net Profit
NOV
NOV
ONC
ONC
Q1 26
$20.0M
Q4 25
$-78.0M
$66.5M
Q3 25
$42.0M
$124.8M
Q2 25
$108.0M
$94.3M
Q1 25
$73.0M
$1.3M
Q4 24
$160.0M
$-151.9M
Q3 24
$130.0M
$-121.3M
Q2 24
$226.0M
$-120.4M
Gross Margin
NOV
NOV
ONC
ONC
Q1 26
18.5%
Q4 25
20.3%
90.5%
Q3 25
18.9%
86.1%
Q2 25
20.4%
87.5%
Q1 25
21.3%
85.2%
Q4 24
21.4%
85.8%
Q3 24
21.4%
83.0%
Q2 24
26.6%
85.1%
Operating Margin
NOV
NOV
ONC
ONC
Q1 26
2.3%
Q4 25
4.0%
12.4%
Q3 25
4.9%
11.5%
Q2 25
6.5%
6.7%
Q1 25
7.2%
1.0%
Q4 24
9.0%
-7.0%
Q3 24
8.9%
-12.0%
Q2 24
14.1%
-11.5%
Net Margin
NOV
NOV
ONC
ONC
Q1 26
1.0%
Q4 25
-3.4%
4.4%
Q3 25
1.9%
8.8%
Q2 25
4.9%
7.2%
Q1 25
3.5%
0.1%
Q4 24
6.9%
-13.5%
Q3 24
5.9%
-12.1%
Q2 24
10.2%
-13.0%
EPS (diluted)
NOV
NOV
ONC
ONC
Q1 26
$0.05
Q4 25
$-0.20
$0.05
Q3 25
$0.11
$0.08
Q2 25
$0.29
$0.06
Q1 25
$0.19
$0.00
Q4 24
$0.40
$-0.10
Q3 24
$0.33
$-0.09
Q2 24
$0.57
$-0.09

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
NOV
NOV
ONC
ONC
Cash + ST InvestmentsLiquidity on hand
$1.3B
$4.5B
Total DebtLower is stronger
$1.7B
$836.4M
Stockholders' EquityBook value
$4.4B
Total Assets
$11.1B
$8.2B
Debt / EquityLower = less leverage
0.19×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
NOV
NOV
ONC
ONC
Q1 26
$1.3B
Q4 25
$1.6B
$4.5B
Q3 25
$1.2B
$4.0B
Q2 25
$1.1B
$2.8B
Q1 25
$1.2B
$2.5B
Q4 24
$1.2B
$2.6B
Q3 24
$985.0M
$2.7B
Q2 24
$827.0M
$2.6B
Total Debt
NOV
NOV
ONC
ONC
Q1 26
$1.7B
Q4 25
$1.7B
$836.4M
Q3 25
$1.7B
Q2 25
$1.7B
Q1 25
$1.7B
Q4 24
$1.7B
Q3 24
$1.7B
Q2 24
$1.7B
Stockholders' Equity
NOV
NOV
ONC
ONC
Q1 26
Q4 25
$6.3B
$4.4B
Q3 25
$6.5B
$4.1B
Q2 25
$6.5B
$3.8B
Q1 25
$6.4B
$3.5B
Q4 24
$6.4B
$3.3B
Q3 24
$6.5B
$3.4B
Q2 24
$6.4B
$3.4B
Total Assets
NOV
NOV
ONC
ONC
Q1 26
$11.1B
Q4 25
$11.3B
$8.2B
Q3 25
$11.3B
$7.6B
Q2 25
$11.4B
$6.3B
Q1 25
$11.3B
$5.8B
Q4 24
$11.4B
$5.9B
Q3 24
$11.4B
$5.8B
Q2 24
$11.3B
$5.7B
Debt / Equity
NOV
NOV
ONC
ONC
Q1 26
Q4 25
0.27×
0.19×
Q3 25
0.27×
Q2 25
0.27×
Q1 25
0.27×
Q4 24
0.27×
Q3 24
0.27×
Q2 24
0.27×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
NOV
NOV
ONC
ONC
Operating Cash FlowLast quarter
$417.3M
Free Cash FlowOCF − Capex
$51.0M
$379.8M
FCF MarginFCF / Revenue
2.5%
25.4%
Capex IntensityCapex / Revenue
2.5%
Cash ConversionOCF / Net Profit
6.28×
TTM Free Cash FlowTrailing 4 quarters
$876.0M
$941.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
NOV
NOV
ONC
ONC
Q1 26
Q4 25
$573.0M
$417.3M
Q3 25
$352.0M
$402.6M
Q2 25
$191.0M
$263.6M
Q1 25
$135.0M
$44.1M
Q4 24
$591.0M
$75.2M
Q3 24
$359.0M
$188.4M
Q2 24
$432.0M
$-95.6M
Free Cash Flow
NOV
NOV
ONC
ONC
Q1 26
$51.0M
Q4 25
$472.0M
$379.8M
Q3 25
$245.0M
$354.5M
Q2 25
$108.0M
$219.8M
Q1 25
$51.0M
$-12.3M
Q4 24
$473.0M
$-17.3M
Q3 24
$277.0M
$54.7M
Q2 24
$350.0M
$-205.5M
FCF Margin
NOV
NOV
ONC
ONC
Q1 26
2.5%
Q4 25
20.7%
25.4%
Q3 25
11.3%
25.1%
Q2 25
4.9%
16.7%
Q1 25
2.4%
-1.1%
Q4 24
20.5%
-1.5%
Q3 24
12.6%
5.5%
Q2 24
15.8%
-22.1%
Capex Intensity
NOV
NOV
ONC
ONC
Q1 26
Q4 25
4.4%
2.5%
Q3 25
4.9%
3.4%
Q2 25
3.8%
3.3%
Q1 25
4.0%
5.0%
Q4 24
5.1%
8.2%
Q3 24
3.7%
13.3%
Q2 24
3.7%
11.8%
Cash Conversion
NOV
NOV
ONC
ONC
Q1 26
Q4 25
6.28×
Q3 25
8.38×
3.22×
Q2 25
1.77×
2.79×
Q1 25
1.85×
34.71×
Q4 24
3.69×
Q3 24
2.76×
Q2 24
1.91×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

NOV
NOV

Energy Equipment$1.2B58%
Energy Products and Services$897.0M44%

ONC
ONC

Segment breakdown not available.

Related Comparisons